
Feb 23 (Reuters) - ADC Therapeutics SA ADCT.N:
ADC THERAPEUTICS ANNOUNCES AMENDED HEALTHCARE ROYALTY FINANCING AGREEMENT
ADC THERAPEUTICS SA - AGREEMENT REDUCES CHANGE OF CONTROL PAYMENT TO $150 MILLION THROUGH 2027
ADC THERAPEUTICS SA - HEALTHCARE ROYALTY GRANTED WARRANTS TO PURCHASE ABOUT 9.8 MILLION COMMON SHARES, WITH EXERCISE PRICE OF $3.81 PER SHARE
ADC THERAPEUTICS SA - ANTICIPATE MEANINGFUL GROWTH BEGINNING 2027, POTENTIAL PEAK REVENUE IN US COULD REACH $600 MILLION TO $1 BILLION ANNUALLY
ADC THERAPEUTICS SA - IN EVENT OF CHANGE OF CONTROL, HEALTHCARE ROYALTY WILL CONTINUE TO RECEIVE ROYALTIES BY ACQUIRER UNTIL ORIGINAL CAP IS REACHED